相关实验视频

Updated: Jun 1, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

潜在的抗糖尿病,Pro-Arg,通过在分析对杏仁进行选

Xin Gu^1,2, Zhihui Cong^1,3, Di Li¹

¹College of Biology and Food Engineering, Chongqing Three Gorges University, Chongqing, 404100, China.

Plant foods for human nutrition (Dordrecht, Netherlands)

|January 18, 2025

概括

杏仁蛋白衍生Pro-Arg (PR) 通过改善胰岛素抵抗,显示出治疗2型糖尿病的潜力. 这种激活了IRS1/PI3K/AKT/GLUT4通路,提供了一个有前途的治疗候选者.

科学领域:

营养生物化学营养生物化学
分子内分泌学分子内分泌学
药理学药理学是指药理学的学科.

背景情况:

胰岛素抵抗是2型糖尿病 (T2DM) 的关键因素.
杏仁是一种常见的坚果,在改善T2DM患者的胰岛素敏感性方面表现出好处.
识别杏仁中用于T2DM管理的特定生物活性化合物是一个可行的研究方向.

研究的目的:

从杏仁蛋白中选和识别抗糖尿病.
研究已识别的,Pro-Arg (PR) 在缓解胰岛素耐药性的作用机制.

主要方法:

使用in-silico查和基于细胞的测试来识别杏仁蛋白中的潜在抗糖尿病.
用分子模拟来预测的分子标.
分析了关键信号通路组件 (IRS1,PI3K,AKT) 和葡萄糖载体 (GLUT4).

主要成果:

蛋白Pro-Arg (PR) 已从杏仁蛋白中鉴定出来.
PR显著上调了IRS1,PI3K和AKT的酸化.
PR促进了GLUT4的转移,并显示了与AKT1的潜在相互作用,表明IRS1/PI3K/AKT/GLUT4通路的激活.

结论:

Pro-Arg (PR) 是一种来自杏仁蛋白的潜在抗糖尿病.
PR通过激活IRS1/PI3K/AKT/GLUT4信号通路来缓解胰岛素耐药性,可能通过向AKT1.
在T2DM治疗中,PR是开发新型治疗药物的有前途的候选者.

关键词:

在体内进行分析.杏仁是一种杏仁.抗糖尿病是一种抗糖尿病.

更多相关视频

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

Published on: June 25, 2018

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

相关概念视频

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...